GemVax Pancreatic Cancer Vaccine Set For First Launch, By Samsung
This article was originally published in PharmAsia News
Executive Summary
Despite an earlier Phase III setback for its therapeutic pancreatic cancer vaccine Riavax, GemVax & KAEL Co. has signed a new licensing deal with Samsung Pharm under which the latter will handle manufacturing, supplying and commercializing of the first-in-class product in South Korea.